 |
 |
|
|
|  PubMed
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
3 July 2001 | Volume 135 Issue 1 | Pages 1-8
Background: The Heart and Estrogen/progestin Replacement Study (HERS) was the first randomized clinical trial of combined hormone therapy and secondary prevention of coronary events. The trial had overall null results but reported an unexpected increased risk for recurrent events in the initial year, followed by a decrease during the final years.
Objective: To provide additional data on a time trend in risk for recurrent heart disease.
Design: A prospective, observational cohort study of secondary prevention of coronary heart disease.
Setting: Nurses' Health Study.
Patients: 2489 postmenopausal women with previous myocardial infarction or documented atherosclerosis; 213 cases of recurrent nonfatal myocardial infarction or coronary death were identified from 1976 through 1996.
Measurements: Information on hormone status and on recurrent disease was collected by using biennial questionnaires. Multivariable-adjusted relative risks and 95% CIs were calculated from logistic regression models.
Results: A trend of decreasing risk for recurrent major coronary heart disease events with increasing duration of hormone use was observed (P for trend = 0.002). For short-term current users, the multivariate-adjusted relative risk for major coronary heart disease was 1.25 (95% CI, 0.78 to 2.00) compared with never-users. However, after longer-term hormone use, the rate of second events was lower in current users than in never-users (relative risk, 0.38 [CI, 0.22 to 0.66]). No clear differences emerged between users of estrogen alone and users of estrogen combined with progestin. Overall, with up to 20 years of follow-up, the relative risk for a second event among current users of hormone therapy was 0.65 (CI, 0.45 to 0.95) compared with never-users.
Conclusions: The risk for recurrent major coronary events seems to increase among short-term hormone users with previous coronary disease but to decrease with longer-term use.
Author and Article Information
From Channing Laboratory, Brigham and Women's Hospital, Harvard Medical School, and Harvard School of Public Health, Boston, Massachusetts.
Acknowledgment: The authors thank Drs. Frank Speizer and Graham Colditz for their support.
Grant Support: By grants CA40356 and HL34594 from the National Institutes of Health. Dr. Grodstein is partially supported by grant AG13482 from the National Institute of Aging and a New Scholars Award from the Ellison Medical Foundation.
Requests for Single Reprints: Francine Grodstein, ScD, Channing Laboratory, 181 Longwood Avenue, Boston, MA 02115.
Current Author Addresses: Dr. Grodstein: Channing Laboratory, 181 Longwood Avenue, Boston, MA 02115.
Dr. Manson: Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, 900 Commonwealth Avenue East, Boston, MA 02215.
Dr. Stampfer: Department of Epidemiology, Harvard School of Public Health, 677 Huntington Avenue, Boston, MA 02115.
Author Contributions: Conception and design: F. Grodstein, J.E. Manson, M.J. Stampfer.
Analysis and interpretation of the data: F. Grodstein, J.E. Manson, M.J. Stampfer.
Drafting of the article: F. Grodstein.
Critical revision of the article for important intellectual content: J.E. Manson, M.J. Stampfer.
Final approval of the article: F. Grodstein, J.E. Manson, M.J. Stampfer.
Statistical expertise: F. Grodstein, M.J. Stampfer.
Obtaining of funding: J.E. Manson.
Administrative, technical, or logistic support: F. Grodstein, J.E. Manson, M.J. Stampfer.
Collection and assembly of data: F. Grodstein, J.E. Manson. ARTICLE
Postmenopausal Hormone Use and Secondary Prevention of Coronary Events in the Nurses' Health Study: A Prospective, Observational Study
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  J. L Ockrim and P. D Abel Long term androgen deprivation therapy in prostate cancer BMJ, September 22, 2008; 337(sep22_1): a1361 - a1361. [Full Text]
|
|
|
|
 |
|
 V. M. Miller and S. P. Duckles Vascular Actions of Estrogens: Functional Implications Pharmacol. Rev., June 1, 2008; 60(2): 210 - 241. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Authors/Task Force Members:, G. Mancia, G. De Backer, A. Dominiczak, R. Cifkova, R. Fagard, G. Germano, G. Grassi, A. M. Heagerty, S. E. Kjeldsen, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur. Heart J., June 11, 2007; (2007) ehm236v1. [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Rossouw, R. L. Prentice, J. E. Manson, L. Wu, D. Barad, V. M. Barnabei, M. Ko, A. Z. LaCroix, K. L. Margolis, and M. L. Stefanick Postmenopausal Hormone Therapy and Risk of Cardiovascular Disease by Age and Years Since Menopause JAMA, April 4, 2007; 297(13): 1465 - 1477. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. Koh and B.-K. Yoon Controversies regarding hormone therapy: Insights from inflammation and hemostasis Cardiovasc Res, April 1, 2006; 70(1): 22 - 30. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Caspard, A. K Chan, and A. M Walker Determinants of the Differences in LDL-Cholesterol After Initiation of Statin Treatment Ann. Pharmacother., January 1, 2006; 40(1): 21 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. B. Petitti and D. A. Freedman Invited Commentary: How Far Can Epidemiologists Get with Statistical Adjustment? Am. J. Epidemiol., September 1, 2005; 162(5): 415 - 418. [Full Text] [PDF]
|
|
|
|
|
|
Y. T. van der Schouw and D. E. Grobbee Menopausal complaints, oestrogens, and heart disease risk: an explanation for discrepant findings on the benefits of post-menopausal hormone therapy Eur. Heart J., July 2, 2005; 26(14): 1358 - 1361. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Dick, C. Sherif, S. Sabeti, J. Amighi, E. Minar, and M. Schillinger Gender Differences in Outcome of Conservatively Treated Patients With Asymptomatic High Grade Carotid Stenosis Stroke, June 1, 2005; 36(6): 1178 - 1183. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Nguyen, D. R. Liles, P. H. Lin, and R. L. Bush Hormone Replacement Therapy and Peripheral Vascular Disease in Women Vascular and Endovascular Surgery, November 1, 2004; 38(6): 547 - 556. [Abstract] [PDF]
|
|
|
|
 |
|
 K. M. Prestwood, C. Unson, M. Kulldorff, and M. Cushman The Effect of Different Doses of Micronized 17{beta}-Estradiol on C-Reactive Protein, Interleukin-6, and Lipids in Older Women J. Gerontol. A Biol. Sci. Med. Sci., August 1, 2004; 59(8): M827 - M832. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A Lawlor, G. Davey Smith, and S. Ebrahim Commentary: The hormone replacement-coronary heart disease conundrum: is this the death of observational epidemiology? Int. J. Epidemiol., June 1, 2004; 33(3): 464 - 467. [Full Text] [PDF]
|
|
|
|
 |
|
 Canadian Task Force on Preventive Health Care Postmenopausal hormone replacement therapy for primary prevention of cardiovascular and cerebrovascular disease: Recommendation statement from the Canadian Task Force on Preventive Health Care Can. Med. Assoc. J., April 27, 2004; 170(9): 1388 - 1389. [Full Text] [PDF]
|
|
|
|
 |
|
 W. B. Kannel and D. Levy Menopause, Hormones, and Cardiovascular Vulnerability in Women Arch Intern Med, March 8, 2004; 164(5): 479 - 481. [Full Text] [PDF]
|
|
|
|
|
|
R. G. Barr, C. C. Wentowski, F. Grodstein, S. C. Somers, M. J. Stampfer, J. Schwartz, F. E. Speizer, and C. A. Camargo Jr Prospective Study of Postmenopausal Hormone Use and Newly Diagnosed Asthma and Chronic Obstructive Pulmonary Disease Arch Intern Med, February 23, 2004; 164(4): 379 - 386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Iemolo, A. Martiniuk, D. A. Steinman, and J. D. Spence Sex Differences in Carotid Plaque and Stenosis Stroke, February 1, 2004; 35(2): 477 - 481. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Newton, A. Z. LaCroix, S. R. Heckbert, L. Abraham, D. McCulloch, and W. Barlow Estrogen Therapy and Risk of Cardiovascular Events Among Women With Type 2 Diabetes Diabetes Care, October 1, 2003; 26(10): 2810 - 2816. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E van der Elst, H. Buurma, M. L Bouvy, and A. de Boer Drug Therapy for Prevention of Recurrent Myocardial Infarction Ann. Pharmacother., October 1, 2003; 37(10): 1465 - 1477. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. P. Reiner, S. R. Heckbert, H. L. Vos, R. A. S. Ariens, R. N. Lemaitre, N. L. Smith, T. Lumley, T. D. Rea, L. A. Hindorff, G. D. Schellenbaum, et al. Genetic variants of coagulation factor XIII, postmenopausal estrogen therapy, and risk of nonfatal myocardial infarction Blood, July 1, 2003; 102(1): 25 - 30. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Grodstein, T. B. Clarkson, and J. E. Manson Understanding the Divergent Data on Postmenopausal Hormone Therapy N. Engl. J. Med., February 13, 2003; 348(7): 645 - 650. [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Herrington Hormone Replacement Therapy and Heart Disease: Replacing Dogma With Data Circulation, January 7, 2003; 107(1): 2 - 4. [Full Text] [PDF]
|
|
|
|
|
|
A. Ferrara, C. P. Quesenberry, A. J. Karter, C. W. Njoroge, A. S. Jacobson, and J. V. Selby Current Use of Unopposed Estrogen and Estrogen Plus Progestin and the Risk of Acute Myocardial Infarction Among Women With Diabetes: The Northern California Kaiser Permanente Diabetes Registry, 1995-1998 Circulation, January 7, 2003; 107(1): 43 - 48. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Radford, T. Church, F. E. Speizer, B. E. Pearson Murphy, S. R. Davis, H. G. Burger, W. H. Goodson III, H. R. Franke, I. Lev, A. Lahad, et al. Risks of Postmenopausal Hormone Replacement JAMA, December 11, 2002; 288(22): 2819 - 2824. [Full Text] [PDF]
|
|
|
|
|
|
A. Decensi, U. Omodei, C. Robertson, B. Bonanni, A. Guerrieri-Gonzaga, F. Ramazzotto, H. Johansson, S. Mora, M. T. Sandri, M. Cazzaniga, et al. Effect of Transdermal Estradiol and Oral Conjugated Estrogen on C-Reactive Protein in Retinoid-Placebo Trial in Healthy Women Circulation, September 3, 2002; 106(10): 1224 - 1228. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. N. Butler, M. Fossel, S. M. Harman, C. B. Heward, S. J. Olshansky, T. T. Perls, D. J. Rothman, S. M. Rothman, H. R. Warner, M. D. West, et al. Is There an Antiaging Medicine? J. Gerontol. A Biol. Sci. Med. Sci., September 1, 2002; 57(9): B333 - 338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Dwyer, C. K. Nordstrom, C. N. Bairey Merz, and J. H. Dwyer Carotid Wall Thickness and Years Since Bilateral Oophorectomy: The Los Angeles Atherosclerosis Study Am. J. Epidemiol., September 1, 2002; 156(5): 438 - 444. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. L. Humphrey, B. K.S. Chan, and H. C. Sox Postmenopausal Hormone Replacement Therapy and the Primary Prevention of Cardiovascular Disease Ann Intern Med, August 20, 2002; 137(4): 273 - 284. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Writing Group for the Women's Health Initiative In Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial JAMA, July 17, 2002; 288(3): 321 - 333. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. W. Fletcher and G. A. Colditz Failure of Estrogen Plus Progestin Therapy for Prevention JAMA, July 17, 2002; 288(3): 366 - 368. [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Herrington, E. Vittinghoff, T. D. Howard, D. A. Major, J. Owen, D. M. Reboussin, D. Bowden, V. Bittner, J. A. Simon, D. Grady, et al. Factor V Leiden, Hormone Replacement Therapy, and Risk of Venous Thromboembolic Events in Women With Coronary Disease Arterioscler. Thromb. Vasc. Biol., June 1, 2002; 22(6): 1012 - 1017. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Barrett-Connor, D. Grady, A. Sashegyi, P. W. Anderson, D. A. Cox, K. Hoszowski, P. Rautaharju, K. D. Harper, and for the MORE Investigators Raloxifene and Cardiovascular Events in Osteoporotic Postmenopausal Women: Four-Year Results From the MORE (Multiple Outcomes of Raloxifene Evaluation) Randomized Trial JAMA, February 20, 2002; 287(7): 847 - 857. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E Rossouw Hormones, genetic factors, and gender differences in cardiovascular disease Cardiovasc Res, February 15, 2002; 53(3): 550 - 557. [Full Text] [PDF]
|
|
|
|
|
|
J M Dixon Hormone replacement therapy and the breast BMJ, December 15, 2001; 323(7326): 1381 - 1382. [Full Text] [PDF]
|
|
|
|
|
|
M. E. Mendelsohn and R. H. Karas The Time Has Come to Stop Letting the HERS Tale Wag the Dogma Circulation, November 6, 2001; 104(19): 2256 - 2259. [Full Text] [PDF]
|
|
|
|
|
|
S. D. Fihn, S. V. Williams, J. Daley, and R. J. Gibbons Guidelines for the Management of Patients with Chronic Stable Angina: Treatment Ann Intern Med, October 16, 2001; 135(8_Part_1): 616 - 632. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D.M. Herrington Effects of oestrogen on cardiovascular events in postmenopausal women Eur. Heart J. Suppl., October 1, 2001; 3(suppl_M): M7 - M11. [Abstract] [PDF]
|
|
|
|
 |
|
 More Data Against HRT Use for Secondary Prevention Journal Watch Cardiology, August 17, 2001; 2001(817): 2 - 2. [Full Text]
|
|
|
|
|
|
K. K. Koh, W. H. Schenke, M. A. Waclawiw, G. Csako, and R. O. Cannon III Statin Attenuates Increase in C-Reactive Protein During Estrogen Replacement Therapy in Postmenopausal Women Circulation, April 2, 2002; 105(13): 1531 - 1533. [Abstract] [Full Text] [PDF]
|
|
